摘要
The gut microbiome is emerging as a pivotal player in the pathogenesis and development of autoimmune diseases(ADs)[1].A comprehensive understanding of the interaction among gut microbiota,drug metabolism,and host immune reaction will shed light on the development of precision medicine for ADs.Microbiota-based interventions,such as specific diet,probiotics/prebiotics,or restricted consortium transplantation,have shown promising preventive and therapeutic potentials in pre-clinical and clinical trials[2].
作者
王忞
刘昱东
赵丽丹
张烜
Min Wang;Yudong Liu;Lidan Zhao;Xuan Zhang(Department of Rheumatology,Beijing Hospital,National Center of Gerontology,Institute of Geriatric Medicine,Chinese Academy of Medical Sciences,Beijing 100730,China;Clinical Immunology Center,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100730,China;The Key Laboratory of Geriatrics,Beijing Institute of Geriatrics,Institute of Geriatric Medicine,Chinese Academy of Medical Sciences,Beijing Hospital/National Center of Gerontology of National Health Commission,Beijing 100730,China;Department of Rheumatology and Clinical Immunology,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100730,China;National Clinical Research Center for Dermatologic and Immunologic Diseases,Ministry of Science&Technology,Beijing 100730,China)
基金
supported by the National Natural Science Foundation of China(81788101,81630044,82071840,81771763,82171798,and 81801635)
the CAMS Innovation Fund for Medical Sciences(CIFMS)(2021-I2M-1-017,2021-I2M-1-047,2021-I2M-1040,2021-I2M-1-016,2021-I2M-1-026,and 2020-I2M-C&T-B013)
Beijing Capital Health Development Fund(2020-2-4019)。
